Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
2000 2
2001 1
2002 1
2003 2
2004 5
2005 2
2006 2
2007 1
2008 4
2009 12
2010 11
2011 10
2012 17
2013 12
2014 8
2015 8
2016 18
2017 14
2018 12
2019 19
2020 26
2021 25
2022 37
2023 29
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

269 results

Results by year

Filters applied: . Clear all
Page 1
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. Horn L, et al. N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280641 Clinical Trial.
Reduced lung-cancer mortality with low-dose computed tomographic screening.
National Lung Screening Trial Research Team; Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. National Lung Screening Trial Research Team, et al. N Engl J Med. 2011 Aug 4;365(5):395-409. doi: 10.1056/NEJMoa1102873. Epub 2011 Jun 29. N Engl J Med. 2011. PMID: 21714641 Free PMC article. Clinical Trial.
The National Lung Screening Trial: overview and study design.
National Lung Screening Trial Research Team; Aberle DR, Berg CD, Black WC, Church TR, Fagerstrom RM, Galen B, Gareen IF, Gatsonis C, Goldin J, Gohagan JK, Hillman B, Jaffe C, Kramer BS, Lynch D, Marcus PM, Schnall M, Sullivan DC, Sullivan D, Zylak CJ. National Lung Screening Trial Research Team, et al. Radiology. 2011 Jan;258(1):243-53. doi: 10.1148/radiol.10091808. Epub 2010 Nov 2. Radiology. 2011. PMID: 21045183 Free PMC article. Clinical Trial.
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Guisier F, Urban T, Ligeza-Poisson C, Planchard D, Amour E, Morin F, Moro-Sibilot D, Zalcman G; French Cooperative Thoracic Intergroup. Scherpereel A, et al. Among authors: do p. Lancet Oncol. 2019 Feb;20(2):239-253. doi: 10.1016/S1470-2045(18)30765-4. Epub 2019 Jan 16. Lancet Oncol. 2019. PMID: 30660609 Clinical Trial.
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R; GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Guigay J, et al. Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5. Lancet Oncol. 2021. PMID: 33684370 Clinical Trial.
The NCI Genomic Data Commons.
Heath AP, Ferretti V, Agrawal S, An M, Angelakos JC, Arya R, Bajari R, Baqar B, Barnowski JHB, Burt J, Catton A, Chan BF, Chu F, Cullion K, Davidsen T, Do PM, Dompierre C, Ferguson ML, Fitzsimons MS, Ford M, Fukuma M, Gaheen S, Ganji GL, Garcia TI, George SS, Gerhard DS, Gerthoffert F, Gomez F, Han K, Hernandez KM, Issac B, Jackson R, Jensen MA, Joshi S, Kadam A, Khurana A, Kim KMJ, Kraft VE, Li S, Lichtenberg TM, Lodato J, Lolla L, Martinov P, Mazzone JA, Miller DP, Miller I, Miller JS, Miyauchi K, Murphy MW, Nullet T, Ogwara RO, Ortuño FM, Pedrosa J, Pham PL, Popov MY, Porter JJ, Powell R, Rademacher K, Reid CP, Rich S, Rogel B, Sahni H, Savage JH, Schmitt KA, Simmons TJ, Sislow J, Spring J, Stein L, Sullivan S, Tang Y, Thiagarajan M, Troyer HD, Wang C, Wang Z, West BL, Wilmer A, Wilson S, Wu K, Wysocki WP, Xiang L, Yamada JT, Yang L, Yu C, Yung CK, Zenklusen JC, Zhang J, Zhang Z, Zhao Y, Zubair A, Staudt LM, Grossman RL. Heath AP, et al. Among authors: do pm. Nat Genet. 2021 Mar;53(3):257-262. doi: 10.1038/s41588-021-00791-5. Nat Genet. 2021. PMID: 33619384 No abstract available.
Engineered Cytokines for Cancer and Autoimmune Disease Immunotherapy.
Uricoli B, Birnbaum LA, Do P, Kelvin JM, Jain J, Costanza E, Chyong A, Porter CC, Rafiq S, Dreaden EC. Uricoli B, et al. Among authors: do p. Adv Healthc Mater. 2021 Aug;10(15):e2002214. doi: 10.1002/adhm.202002214. Epub 2021 Mar 9. Adv Healthc Mater. 2021. PMID: 33690997 Free PMC article. Review.
[Malignant mesothelioma and constitutional BAP1 gene mutations].
Neviere Z, Berthet P, Polycarpe F, Dubos-Arvis C, Dô P, Gervais R. Neviere Z, et al. Among authors: do p. Rev Mal Respir. 2019 Feb;36(2):241-248. doi: 10.1016/j.rmr.2017.11.014. Epub 2019 Jan 24. Rev Mal Respir. 2019. PMID: 30686559 Review. French.
269 results